Skip to main content
. Author manuscript; available in PMC: 2022 Oct 4.
Published in final edited form as: Pediatr Res. 2021 Oct 8;92(2):415–423. doi: 10.1038/s41390-021-01747-5

Figure 5. Azithromycin (AZ) Treatment Attenuates PAM-amplified Hypoxic-Ischemic (HI) Neuropathology.

Figure 5.

Panels a-f illustrate representative cresyl-violet stained coronal brain sections, obtained at P35, in samples from the 3 groups compared in Fig. 4. a–d. P7 rats received injections of Pam3CSK4, followed by initiation 60 min HI (PAM+HI; see Methods). Two h after the end of HI, animals started treatment with saline (a, b), the 3-dose AZ regimen (c, d; AZ*3), or the 5-dose AZ regimen (e, f; AZ*5). In a representative control sample (a, b), right hemisphere, striatal (*), and hippocampal (arrow) atrophy along with cortical thinning (arrowhead, a) or cystic encephalomalacia (arrowhead, b) are evident. A representative AZ*3 sample (c, d) illustrates subtle right hemisphere tissue loss, striatal atrophy (*), and mild hippocampal atrophy together with pyramidal cell layer thinning (arrow). A representative AZ*5 sample (e, f) demonstrates mild right striatal (*) and hippocampal (arrow) tissue loss but no evidence of cortical injury. (Scale bar = 2 mm).